FindTrial
Sign In

Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02027064
Enrollment
40
Registered
2014-01-03
Start date
2013-10-31
Completion date
2017-10-31
Last updated
2016-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Brief summary

molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT) is still a problem even after donor lymphocyte infusion. Interferon seemed to augment graft-versus-leukemia (GVL) effect in this part of patients. the study is to evaluate the safety and efficacy of interferon for the intervention of molecular relapse in t (8; 21) acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)

Interventions

DRUGInterferon-alpha

Sponsors

Peking University People's Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 65 Years
Healthy volunteers
No

Inclusion criteria

* high risk t (8; 21) AML * molecular relapse after allo-SCT

Exclusion criteria

* active graft-versus-host disease * uncontrolled severe infection * organ function failure

Design outcomes

Primary

MeasureTime frameDescription
relapse rateparticipants will be followed for an expected average of 365 daysnumber of participants with morphologic relapse at one year

Countries

China

Contacts

Primary Contactyu wang, M.D.
ywyw3172@sina.com861088326666

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026